Modus Therapeutics : engages Lago Kapital as a liquidity guarantor

STOCKHOLM, SWEDENOctober 21, 2021: Modus Therapeutics Holding AB (“Modus Therapeutics”) announces that it has engaged Lago Kapital as liquidity guarantor for the shares of the company. The liquidity guarantee begins to run from 22 October 2021.

In its mission of guarantor of liquidity, Lago Kapital will guarantee the possibility of trading the shares of the company by permanently placing negotiating elements on each buy and sell page of the order book. This complies with the Nasdaq First North Growth Market regulations regarding the liquidity guarantee and means that the liquidity guarantor allocates the buying and selling volume corresponding to at least 15,000 SEK with a maximum difference of 4% between the purchase and sale price. The aim of the liquidity guarantee is to improve the liquidity of the stock and to reduce the difference between the bid price and the ask price when trading in progress.

For this purpose, Development of Karolinska loans 40,000 MODTX shares to Lago Kapital free of charge.

For more information on Therapeutic Modus, please contact:

John Öhd, VD, Therapeutic Modus

Telephone: +46 (0) 70 766 80 97

E-post: [email protected]

Certified advisor

Svensk Kapitalmarknadsgranskning AB

Telephone: +46 11 32 30 732

E-post: [email protected]

On Therapeutic Modus and sevuparin

Therapeutic Modus is a Swedish biotechnology company headquartered in Stockholm who develops sevuparin with a focus on diseases with a high unmet medical need. The company’s goal in the near future is to develop sevuparin for patients with sepsis / septic shock, which is a serious and often fatal disease. Therapeutic Modus is listed on the Nasdaq First North Growth market (“MODTX”). More information is available at

Sevuparin is a clinically innovative, patented polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-stick and anti-aggregate effects. Sevuparin is a heparinoid with markedly weakened anticoagulant characteristics which allows doses to be administered several times higher than ordinary heparinoids without the associated risk of hemorrhagic side effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for hospital administration and a subcutaneous formulation which allows ambulatory and home administration.,c3437764

(c) Decision 2021. All rights reserved., source Press Releases – English

Source link

Comments are closed.